In data shown at the EADV Congress in Vienna, 39% of GLP-1 users reported nails lifting versus 9% of non-users. Researchers say the findings are self-reported and show association, not cause.
Recap by typeshit. Full story at Yahoo Creators.
European regulators first raised NAION, a rare optic nerve condition sometimes called an eye stroke, as a possible risk more than 15 months ago.
Obesity doctor Spencer Nadolsky takes on six popular misconceptions about Ozempic in a quick social video. The caption doesn't say which myths are covered.
Users described more appetite, fatigue, extra energy and insomnia. An analysis of Reddit comments, not a clinical trial, so the findings come from self-reports.
A piece on questions about tirzepatide and breast cancer risk. Only the headline is available, so check the source for what the evidence says.
A new survey points to a hard money choice for some Americans: paying for Ozempic or putting that cash toward retirement. NewsNation has the numbers.
NYU's Dr Holly Lofton says some patients using gray-market reta saw no weight loss, and both experts warn against buying it online while it remains unapproved in the UK.
Loading…